Page last updated: 2024-12-05

oxypertine

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Oxypertine is a drug that acts as a selective serotonin reuptake inhibitor (SSRI) and has shown potential as a treatment for anxiety disorders. It was initially developed in the 1960s and has been studied in various clinical trials for its efficacy in treating generalized anxiety disorder (GAD), obsessive-compulsive disorder (OCD), and other conditions. Oxypertine's mechanism of action involves inhibiting the reuptake of serotonin in the brain, leading to increased serotonin levels in the synaptic cleft. This increase in serotonin neurotransmission is believed to contribute to its anxiolytic effects. Studies have indicated that oxypertine can be effective in reducing anxiety symptoms and improving quality of life in individuals with GAD. However, further research is needed to fully understand its therapeutic potential and to determine its optimal dosage and long-term safety. The synthesis of oxypertine involves a complex chemical process that has been described in the scientific literature. The drug's importance lies in its potential as a novel treatment option for anxiety disorders, particularly for those who do not respond well to other available therapies. The ongoing research on oxypertine aims to clarify its therapeutic benefits, establish its safety profile, and explore its potential in other psychiatric conditions.'

oxypertine: was heading 1975-94 (see under INDOLES 1975-90); use PIPERAZINES to search OXYPERTINE 1975-94; antipsychotic agent also used in severe depression; it has potentially dangerous side effects [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID4640
CHEMBL ID2107011
CHEBI ID31952
SCHEMBL ID1515
MeSH IDM0224683

Synonyms (52)

Synonym
indole, 5,6-dimethoxy-2-methyl-3-(2-(4-phenyl-1-piperazinyl)ethyl)-
oxipertinum
1h-indole, 5,6-dimethoxy-2-methyl-3-(2-(4-phenyl-1-piperazinyl)ethyl)-
oxypertine [usan:inn:ban:jan]
oxypertinum [inn-latin]
do 180
5,6-dimethoxy-2-methyl-3-(2-(4-phenyl-1-piperazinyl)ethyl)indole
opertil
forit
einecs 205-818-3
equipertine
brn 0899339
oxipertina [inn-spanish]
oxypertine
win 18501-2
D01219
153-87-7
oxypertine (jan/usan/inn)
forit (tn)
5,6-dimethoxy-2-methyl-3-[2-(4-phenylpiperazin-1-yl)ethyl]-1h-indole
NCGC00183866-01
oxipertina
oxypertinum
5-23-03-00112 (beilstein handbook reference)
unii-5jgl4g25r7
win 18,501-2
5jgl4g25r7 ,
(r)-1,1'-binaphthyl-2,2'-diyl bis(trifluoromethanesulfonate)
win-18501-2
CHEMBL2107011
win-185012
oxipertine
SCHEMBL1515
oxypertine [mi]
5,6-dimethoxy-2-methyl-3-[2-(4-phenyl-1-piperazinyl)ethyl]indole
oxypertine [who-dd]
oxypertine [usan]
oxypertine [jan]
oxypertine [inn]
oxypertine [mart.]
oxypertin
5,6-dimethoxy-2-methyl-3-[2-(4-phenyl-1-piperazinyl)ethyl]-1h-indole #
1h-indole, 5,6-dimethoxy-2-methyl-3-[2-(4-phenyl-1-piperazinyl)ethyl]-
DTXSID20165185
CHEBI:31952
5,6-dimethoxy-2-methyl-3-[2-(4-phenyl-1-piperazinyl)ethyl]-1h-indole
5,6-dimethoxy-2-methyl-3-(2-(4-phenylpiperazin-1-yl)ethyl)-1h-indole
DB13403
Q7116102
CS-0077804
HY-119677
AKOS040749106

Research Excerpts

[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
organic molecular entityAny molecular entity that contains carbon.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Bioassays (19)

Assay IDTitleYearJournalArticle
AID1079931Moderate liver toxicity, defined via clinical-chemistry results: ALT or AST serum activity 6 times the normal upper limit (N) or alkaline phosphatase serum activity of 1.7 N. Value is number of references indexed. [column 'BIOL' in source]
AID1079948Times to onset, minimal and maximal, observed in the indexed observations. [column 'DELAI' in source]
AID1079935Cytolytic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is > 5 (see ACUTE). Value is number of references indexed. [column 'CYTOL' in source]
AID1079947Comments (NB not yet translated). [column 'COMMENTAIRES' in source]
AID1079939Cirrhosis, proven histopathologically. Value is number of references indexed. [column 'CIRRH' in source]
AID1079945Animal toxicity known. [column 'TOXIC' in source]
AID1079934Highest frequency of acute liver toxicity observed during clinical trials, expressed as a percentage. [column '% AIGUE' in source]
AID1079943Malignant tumor, proven histopathologically. Value is number of references indexed. [column 'T.MAL' in source]
AID1079933Acute liver toxicity defined via clinical observations and clear clinical-chemistry results: serum ALT or AST activity > 6 N or serum alkaline phosphatases activity > 1.7 N. This category includes cytolytic, choleostatic and mixed liver toxicity. Value is
AID1079932Highest frequency of moderate liver toxicity observed during clinical trials, expressed as a percentage. [column '% BIOL' in source]
AID1079940Granulomatous liver disease, proven histopathologically. Value is number of references indexed. [column 'GRAN' in source]
AID1079949Proposed mechanism(s) of liver damage. [column 'MEC' in source]
AID1079944Benign tumor, proven histopathologically. Value is number of references indexed. [column 'T.BEN' in source]
AID1079941Liver damage due to vascular disease: peliosis hepatitis, hepatic veno-occlusive disease, Budd-Chiari syndrome. Value is number of references indexed. [column 'VASC' in source]
AID1079936Choleostatic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is < 2 (see ACUTE). Value is number of references indexed. [column 'CHOLE' in source]
AID1079937Severe hepatitis, defined as possibly life-threatening liver failure or through clinical observations. Value is number of references indexed. [column 'MASS' in source]
AID1079942Steatosis, proven histopathologically. Value is number of references indexed. [column 'STEAT' in source]
AID1079938Chronic liver disease either proven histopathologically, or through a chonic elevation of serum amino-transferase activity after 6 months. Value is number of references indexed. [column 'CHRON' in source]
AID1079946Presence of at least one case with successful reintroduction. [column 'REINT' in source]
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (9)

TimeframeStudies, This Drug (%)All Drugs %
pre-19902 (22.22)18.7374
1990's3 (33.33)18.2507
2000's4 (44.44)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 27.66

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index27.66 (24.57)
Research Supply Index2.64 (2.92)
Research Growth Index4.51 (4.65)
Search Engine Demand Index31.58 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (27.66)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials2 (18.18%)5.53%
Reviews0 (0.00%)6.00%
Case Studies1 (9.09%)4.05%
Observational0 (0.00%)0.25%
Other8 (72.73%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]